Intravenous (IV) Solution Manufacturing in the US - Industry Market Research Report

Life Line: An Increase in Insured US Citizens is Expected to Stimulate Industry Demand

Intravenous (IV) Solution Manufacturing in the US

Intravenous (IV) solution manufacturers supply hospitals and healthcare facilities with essential IV products. The steady growth in hospital demand and the crucial nature of medical treatments have provided some safeguards against economic downturns. In 2020, when faced with COVID-19 restrictions, industry revenue increased as most hospitalized patients needed IV products. But rising plastic materials and resin costs paired with a decline in overall health expenditure have curbed growth rates. As a result, industry-wide revenue has grown at a modest CAGR of 0.2% to $2.0 billion over the five years to 2023, including a 3.6% bounce back in revenue in 2023 alone.

Companies in this industry primarily engage in manufacturing substances that may be infused directly into a vein using a venous access device. Intravenous (IV) solutions may be used to correct electrolyte imbalances, to deliver medications, for blood transfusion or as fluid replacement. Solutions specifically for animals are excluded from this industry.

This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.